Oxepanes
Apexbio Technology LLC FHD-286-25MG
FHD-286 (CAS No 2671128-05-3) is a novel compound in the field of biomedical research primarily categorized under oncology Originally developed from a series of studies exploring targeted cancer therapies FHD-286 acts by inhibiting specific signaling pathways that are crucial for tumor cell proliferation and survival It exhibits potent activity within the nanomolar to low micromolar range making it a valuable tool for in vitro experiments Common applications include its use in various cell models such as breast and lung cancer cells as well as in vivo studies involving xenograft models in mice Additionally FHD-286 is frequently utilized in drug screening programs focused on identifying new therapeutic agents against resistant cancer types Experimental concentrations are typically dependent on the specific research design allowing for tailored applications in diverse experimental settings
Apexbio Technology LLC FHD-286-1MG
FHD-286 (CAS No 2671128-05-3) is a novel compound in the field of biomedical research primarily categorized under oncology Originally developed from a series of studies exploring targeted cancer therapies FHD-286 acts by inhibiting specific signaling pathways that are crucial for tumor cell proliferation and survival It exhibits potent activity within the nanomolar to low micromolar range making it a valuable tool for in vitro experiments Common applications include its use in various cell models such as breast and lung cancer cells as well as in vivo studies involving xenograft models in mice Additionally FHD-286 is frequently utilized in drug screening programs focused on identifying new therapeutic agents against resistant cancer types Experimental concentrations are typically dependent on the specific research design allowing for tailored applications in diverse experimental settings